ArticleCell reports2023
Periostin activates distinct modules of inflammation and itching downstream of the type 2 inflammation pathway.
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- Periostin drives psoriasis progression through the stimulation of cutaneous nerve fibers.iScience · 2026Article
- SM17, an anti-interleukin-17 receptor B antibody, ameliorates pathogenesis of chronic rhinosinusitis with nasal polyps and idiopathic pulmonary fibrosisERJ open research · 2026Article
- The Past, the Present, and the Future of Periostin in Allergy.Allergy, asthma & immunology research · 2026Review
- Engineered atopic dermatitis models for recreating hypoxic conditions in atopic dermatitis microenvironments.Bioactive materials · 2026Article
- Cross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines.Current allergy and asthma reports · 2026Review
- Role of Periostin in the Development of Nasal Hyperresponsiveness in Mice with Allergic Rhinitis.International journal of molecular sciences · 2026Article
- Serum periostin levels in myocardial infarction: Findings from forensic autopsy cases.PloS one · 2026Article
- Prediction of early responses to dupilumab treatment in patients with moderate-to-severe atopic dermatitis by a machine learning model integrating clinical characteristics and serum biomarkers.Postepy dermatologii i alergologii · 2026Article
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.Acta neuropathologica communications · 2025Article
- Serum Periostin is Able to Stratify Type 2-Dominant Ulcerative Colitis.Inflammatory bowel diseases · 2025Article
- Inflammatory Transformation of Skin Basal Cells as a Key Driver of Cutaneous Aging.International journal of molecular sciences · 2025Article
- Type 2 immunity in allergic diseases.Cellular & molecular immunology · 2025Review
- Article
- The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy.Journal of inflammation research · 2025Review
- The Role of Fibroblasts in Atopic Dermatitis: Establishing Proinflammatory Microenvironments and Mediating Cellular Crosstalk.Journal of inflammation research · 2025Review
- Serum Periostin as a Potential Biomarker in the Evaluation of Allergic Rhinitis: A Pilot Study.Journal of asthma and allergy · 2025Article
- Guided monocyte fate to FRβ/CD163Cellular and molecular life sciences : CMLS · 2024Article
- Transcriptomic evidence for T cell-fibroblast-keratinocyte axis via IL-13-periostin-integrin in atopic dermatitis.Allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Atopic dermatitis (AD) is a chronic relapsing skin disease accompanied by recurrent itching. Although type 2 inflammation is dominant in allergic skin inflammation, it is not fully understood how non-type 2 inflammation co-exists with type 2 inflammation or how type 2 inflammation causes itching. We have recently established the FADS mouse, a mouse model of AD. In FADS mice, either genetic disruption or pharmacological inhibition of periostin, a downstream molecule of type 2 inflammation, inhibits NF-κB activation in keratinocytes, leading to downregulating eczema, epidermal hyperplasia, and infiltration of neutrophils, without regulating the enhanced type 2 inflammation. Moreover, inhibition of periostin blocks spontaneous firing of superficial dorsal horn neurons followed by a decrease in scratching behaviors due to itching. Taken together, periostin links NF-κB-mediated inflammation with type 2 inflammation and promotes itching in allergic skin inflammation, suggesting that periostin is a promising therapeutic target for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.